Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Profound Medical (TSE:PRN) Trading Down 2.9% - Should You Sell?

Profound Medical logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Price action: Profound Medical fell 2.9% to C$9.27 (intraday low C$9.14) on below-average volume, trading near its 200-day SMA of C$9.23 with a market cap of C$336.45 million.
  • Mixed fundamentals: The company reported quarterly EPS of C$0.37 on C$8.0M revenue but shows a negative net margin (-248.45%) and negative ROE (-85.73%), while analysts forecast roughly -C$1.90 EPS for the fiscal year.
  • Insider confidence: Director Dr. Arun Menawat purchased 20,000 shares at C$6.96, and corporate insiders now own 8.62% of the company.
  • Five stocks we like better than Profound Medical.

Profound Medical Corp. (TSE:PRN - Get Free Report) traded down 2.9% during trading on Monday . The stock traded as low as C$9.14 and last traded at C$9.27. 9,809 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 19,005 shares. The stock had previously closed at C$9.55.

Profound Medical Stock Down 2.9%

The company's 50 day simple moving average is C$8.78 and its 200-day simple moving average is C$9.23. The company has a current ratio of 12.52, a quick ratio of 14.98 and a debt-to-equity ratio of 7.09. The firm has a market cap of C$336.45 million, a P/E ratio of -6.57 and a beta of 1.07.

Profound Medical (TSE:PRN - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported C$0.37 EPS for the quarter. The firm had revenue of C$8.00 million during the quarter. Profound Medical had a negative net margin of 248.45% and a negative return on equity of 85.73%. Research analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Dr. Arun Menawat bought 20,000 shares of the firm's stock in a transaction on Friday, March 20th. The stock was acquired at an average cost of C$6.96 per share, for a total transaction of C$139,200.00. Following the purchase, the director owned 658,660 shares in the company, valued at approximately C$4,584,273.60. This represents a 3.13% increase in their ownership of the stock. Corporate insiders own 8.62% of the company's stock.

Profound Medical Company Profile

(Get Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Profound Medical Right Now?

Before you consider Profound Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.

While Profound Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines